You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["RNA", "CellLine", "Protein", "DNA", "CellType"].

Please return the output as a JSON object of the format: {"DNA" : ["TAL1", ...], "RNA": ["mRNAs", ...], "CellLine": ["T cells", ...], "CellType": ["monocytes", ...], "Protein": ["IL-2", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells. The design of combination hormonal and immunotherapeutic protocols for breast cancer patients may be facilitated by analysis of preclinical in vitro model systems. Estrogen receptor positive (ER +: MCF-7) and negative (ER -: MDA-MB-231) human breast cancer cell lines were utilized to evaluate the effects of tamoxifen (TAM) and estradiol (E2) on modulation of breast cancer target susceptibility to lysis by lymphokine-activated killer (LAK) cells. E2-stimulated ER + cells were more susceptible to lysis by LAK cells than corresponding TAM-treated or control cells, while treatment of ER-cells with either E2 or TAM alone did not alter from control their susceptibility to this immune-mediated lysis. All ER + and ER-cells tested remained sensitive after treatment with TAM to lysis by LAK cells. In addition, an adenocarcinoma reactive human-mouse chimeric monoclonal antibody (ING-1) was able to significantly boost in vivo generated LAK cell-mediated lysis of control, E2-treated, and TAM-treated ER + and ER-cells. These in vitro results provide a preclinical rationale for in vivo testing of TAM, interleukin-2 (IL-2), and breast cancer reactive antibody-dependent cellular cytotoxicity facilitating antibody in patients with refractory or high risk breast cancer.
{"CellLine": ["E2 - stimulated ER + cells", "human breast cancer cell lines", "ER -", "Estrogen receptor positive (ER +  MCF - 7) and negative (ER -  MDA - MB - 231) human breast cancer cell lines", "control , E2 - treated , and TAM - treated ER + and ER - cells", "ER +  MCF - 7", "ER -  MDA - MB - 231", "ER + and ER - cells", "TAM - treated"], "CellType": ["lymphokine - activated killer (LAK) cells", "LAK cells", "lymphokine - activated killer cells", "control cells"], "DNA": [], "Protein": ["ING - 1", "interleukin - 2", "IL - 2", "adenocarcinoma reactive human - mouse chimeric monoclonal antibody"], "RNA": []}